Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Amortizatization of Intangibles (2023 - 2024)

Lyra Therapeutics (LYRA) has disclosed Amortizatization of Intangibles for 2 consecutive years, with $267000.0 as the latest value for Q4 2024.

  • On a quarterly basis, Amortizatization of Intangibles fell 75.46% to $267000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was $2.3 million, a 34.9% decrease, with the full-year FY2024 number at $2.3 million, down 34.9% from a year prior.
  • Amortizatization of Intangibles was $267000.0 for Q4 2024 at Lyra Therapeutics, down from $401000.0 in the prior quarter.
  • In the past five years, Amortizatization of Intangibles ranged from a high of $1.1 million in Q4 2023 to a low of $267000.0 in Q4 2024.